Appl. No. 10/079,136 Response to Restriction Requirement Dated July 21, 2003 Reply to Office Action of March 21, 2003

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original): An immunogenic composition comprising mycobacteria wherein said mycobacteria comprises modified protein production.

Claim 2 (original): The composition of Claim 1, wherein the modified protein expression comprises an increase in heat shock protein production.

Claim 3 (original): The composition of Claim 2, wherein the heat shock protein is selected from the group consisting of Hsp10, Hsp40, Hsp60, Hsp70, Hsp90, GrpE, ClpB and alpha-cystallin.

Claim 4 (original): The composition of Claim 1, wherein the mycobacteria is selected from the group consisting of *M. tuberculosis*, *M. avium-intracellulare*, *M.bovis*, *M. kansasii*, *M. fortuitum*, *M. chelonae*, *M. leprae*, *M. africanum*, *M. microti* and *M.paratuberculosis*.

Claim 5 (original): The composition of Claim 1, wherein the mycobacteria comprises *M. tuberculosis*.

Claim 6 (original): The composition of Claim 5, wherein the heat shock protein comprises Hsp 60 or Hsp 70.

Claim 7 (original): The composition of Claim 5, wherein the heat shock protein consists of Hsp 60 and Hsp 70.

Claim 8 (original): The composition of Claim 1, further comprising a pharmaceutically acceptable carrier.

Claim 9 (withdrawn): A method for eliciting an immune response in a human or animal comprising to said human or animal an immunogenic composition wherein said composition comprises an pathogenic organism having modified heat shock protein production.

Claim 10 (withdrawn): The method of Claim 9, wherein the pathogenic organism is selected from the group consisting of M. tuberculosis, M. avium-intracellulare, M.bovis, M. kansasii, M. fortuitum, M. chelonae, M. leprae, M. africanum, M. microti and M.paratuberculosis.

Claim 11 (withdrawn): The method of Claim 10, wherein the pathogenic organism comprises *M. tuberculosis* and the modified heat shock protein production comprises an increase in the production of heat shock proteins.

Claim 12 (withdrawn): The method of Claim 11, wherein the heat shock protein is selected from the group consisting of Hsp10, Hsp40, Hsp60, Hsp70, Hsp90, GrpE, ClpB and alpha-cystallin.

Claim 13 (withdrawn): The method of Claim 11, wherein the heat shock proteins consists of Hsp 60 and Hsp 70.

Claim 14 (withdrawn): A method for treating mycobacterial disease comprising administering to a human or animal an immunogenic composition comprising modified mycobacterial pathogens wherein said mycobacterial pathogens have increased heat shock protein production.

Claim 15 (withdrawn): The method of Claim 14, wherein the mycobacterial disease is selected from the group consisting of tuberculosis and Crohn's disease.

Claim 16 (withdrawn): The method of Claim 15, wherein the heat shock protein is selected from the group consisting of Hsp10, Hsp40, Hsp60, Hsp70, Hsp90, GrpE, ClpB and alpha-cystallin.

Appl. No. 10/079,136
Response to Restriction Requirement Dated July 21, 2003
Reply to Office Action of March 21, 2003

Claim 17 (withdrawn): The method of Claim 15, wherein the heat shock protein consists of Hsp 60 and Hsp 70.

Claim 18 (withdrawn): The method of Claim 14, further comprising a pharmaceutically acceptable carrier.

Claim 19 (original): An immunogenic composition comprising an improved BCG vaccine wherein the vaccine comprises modified *M. bovis* having increased heat shock protein production.

Claim 20 (original): The immunogenic composition of Claim 19, wherein the heat shock protein is selected from the group consisting of Hsp10, Hsp40, Hsp60, Hsp70, Hsp90, GrpE, ClpB and alpha-cystallin.